Nursing Elites

1. A client has been taking Phenylephrine nasal drops for the past 10 days for Sinusitis. The nurse should assess the client for which of the following adverse effects of this medication?

• A. Sedation
• B. Nasal congestion
• C. Productive cough
• D. Constipation

Correct answer: B

Rationale: The correct answer is B: Nasal congestion. After more than 5 days of use, nasal sympathomimetic medications like phenylephrine can lead to rebound nasal congestion. This occurs due to prolonged vasoconstriction of nasal blood vessels, causing worsening nasal congestion. Sedation (choice A) is not a common adverse effect of phenylephrine nasal drops. Productive cough (choice C) and constipation (choice D) are also not typical adverse effects associated with this medication.

2. A client who is receiving combination chemotherapy is exhibiting a temperature of 38.1°C (100.6°F). Which of the following findings should the nurse identify as an indication of an oncologic emergency?

• A. Dry oral mucous membranes
• B. Nausea and vomiting
• C. Temperature of 38.1°C (100.6°F)
• D. Anorexia

Correct answer: C

Rationale: A temperature of 38.1°C (100.6°F) can indicate an infection, which is considered an oncologic emergency in clients undergoing chemotherapy due to the heightened risk of sepsis in immunocompromised individuals. Immediate assessment and intervention are crucial to prevent severe complications. Dry oral mucous membranes, nausea and vomiting, and anorexia are common side effects of chemotherapy but are not specific indicators of an oncologic emergency like a fever in this setting.

3. When should Montelukast be taken?

• A. At least two hours before exercise
• B. Daily in the evening
• C. Two hours before exercise or daily in the evening
• D. None of the above

Correct answer: B

Rationale: Montelukast should be taken daily in the evening to effectively manage asthma symptoms. Taking it at the same time each day helps maintain a consistent level of the medication in the body, providing optimal control over asthma symptoms and inflammation. Choice A is incorrect because Montelukast should not be taken specifically before exercise, but rather daily. Choice C is incorrect because although taking Montelukast two hours before exercise is not necessary, taking it daily in the evening is essential for its effectiveness. Choice D is incorrect as Montelukast should be taken daily to manage asthma.

4. A client has a new prescription for Ondansetron. Which of the following statements should the nurse include?

• A. Take the medication 30 minutes before chemotherapy.
• B. Expect your urine to turn orange.
• C. Increase your intake of high-fiber foods.
• D. Avoid drinking grapefruit juice.

Correct answer: A

Rationale: The correct answer is A: 'Take the medication 30 minutes before chemotherapy.' Ondansetron, an antiemetic, should be taken before chemotherapy to prevent nausea and vomiting. Taking it 30 minutes before chemotherapy ensures the medication is most effective in controlling chemotherapy-induced nausea and vomiting. Choices B, C, and D are incorrect. Option B is unrelated to Ondansetron, option C is not necessary for this medication, and option D does not interact with Ondansetron but is relevant for other medications.

5. A healthcare professional is preparing to administer Pamidronate to a client who has bone pain related to cancer. Which of the following precautions should the healthcare professional take when administering pamidronate?

• A. Inspect the IV site for redness and irritation when changing the intravenous patch.
• B. Assess the IV site for thrombophlebitis frequently during administration.
• C. Instruct the client to sit upright or stand for 30 min following intravenous administration.
• D. Watch for manifestations of anaphylaxis for 20 min after intramuscular administration.

Correct answer: B

Rationale: Pamidronate is administered through intravenous (IV) infusion. As this medication can be irritating to veins, the healthcare professional should carefully assess the IV site for thrombophlebitis during administration to prevent potential complications. Choice A is incorrect as Pamidronate is not administered via intradermal patch. Choice C is incorrect as it does not relate to the administration of Pamidronate. Choice D is incorrect as Pamidronate is not administered intramuscularly.

Similar Questions